HoxB13 expression in prostate cancer: clinicopathologic characteristics and role as potential diagnostic marker

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Prostate Cancer
Translational Research
Presenter Yoon Ah Cho
Citation Annals of Oncology (2018) 29 (suppl_9): ix67-ix73. 10.1093/annonc/mdy434
Authors Y.A. Cho, C.K. Park, N.H. Cho
  • Department Of Pathology, Yonsei University, 03722 - Seoul/KR



The origin, histologic criteria or prognostication of prostate ductal type adenocarcinoma (DAC) is relatively unknown to compare with acinar type adenocarcinoma (AAC). Furthermore, selective biomarker for recognition of ductal component has not been discovered. In this study, we investigated clinicopathologic characteristics of HoxB13 expression in prostate cancer, comparing clinicopathologic profiles between DAC and AAC.


Among 3250 consecutive radical prostatectomy (RP) specimens from 2006 to 2015, 75 DAC cohorts were selected. Also, 103 pathologic T stage and Gleason score-matched AAC cases were selected as a control group. Histopathologic evaluation of 178 RP cases was reperformed. Immunohistochemistry for HoxA13, HoxB13, PTEN and ERG was performed on whole section slides. Diagnostic correlation between morphologic and immunophenotypic criteria and interobserver agreement were estimated.


After slide review, 178 RP specimens were reclassified to 68 DACs and 110 AACs. HoxB13 was expressed in 64 out of 178 cases. HoxB13 expression was significantly associated with DAC (P < 0.001) and biochemical recurrence (BCR; P < 0.001). In Kaplan-Meier analysis, HoxB13 expression was associated with shorter BCR-free survival (P < 0.001). On multivariate analysis, HoxB13 expression was associated with shorter BCR-free survival (P < 0.001). Immunophenotypic criteria (kappa value = 0.868) showed higher interobserver agreement than morphologic criteria (kappa value = 0.419) and very strong correlation (Spearman’s correlation coefficient = 0.845; P < 0.001) with morphologic criteria.


HoxB13 can be used as a diagnostic marker for the detection of DAC and a prognostic marker that predicts BCR.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Institutional Review Board of the Severance Hospital.


Ministry of Health & Welfare.


All authors have declared no conflicts of interest.